Speaker Profile

M.D., Ph.D., F.A.C.P., Director, Comprehensive Cancer Center of Wake Forest University; Chair, Department of Cancer Biology Wake Forest Baptist Health Sciences

As Director of the Comprehensive Cancer Center of Wake Forest University, Dr. Pasche holds the Charles L Spurr Endowed Chair in Cancer Research at Wake Forest Baptist Health Sciences and serves as the Chair of the Department of Cancer Biology. He received a M.D. degree from the University of Lausanne (Switzerland), M.D. and Ph.D. degrees from the Karolinska Institute (Stockholm, Sweden), postdoctoral research training at the Brigham and Women’s Hospital, Harvard Medical School, Internal Medicine training at the New York Hospital, Cornell Medical Center, and Hematology/Oncology training at Memorial Sloan-Kettering Cancer Center. He was the founder and Director of Cancer Genetics Program (Northwestern School of Medicine). He was the Chief of the Division of Hematology/Oncology at the University of Alabama at Birmingham and served as Deputy Director at the University of Alabama at Birmingham Comprehensive Cancer Center. Dr. Pasche’s research has focused on cancer susceptibility and new therapies for cancer. He has developed a new medical device for the treatment of hepatocellular carcinoma, which received European regulatory approval in 2018. Dr. Pasche has published more than 120 peer-reviewed articles, book chapters and editorials, many of which appeared in high impact journals.

 Session Abstract – PMWC Silicon Valley

The Molecular Tumor Board (MTB) was mostly established to facilitate the incorporation of molecular diagnostics into the consideration of appropriate therapies for patients with late stage cancer. Initially, much of the deliberation was focused on understanding the results of such testing, as reporting of results was limited in scope and frequently understandable only to cutting edge experts in the field. Improved, but still not perfect, reporting now exists, so discussion has shifted to prognostic and therapeutic considerations. That said, the collective experience with rare mutations and off label therapies is still such that collective wisdom is necessary. This brings up the issue of how MTBs collect, share, and preserve data within a specific MTB, and perhaps more importantly, how it might be shared amongst MTBs and beyond. While initial activity related to MTBs resided almost exclusively in large academic, and select community, medical centers, there is now significant effort in the commercial setting as well, with a number of intriguing efforts presently underway. Important and evolving issues, such as defining which patients are most likely to benefit from the efforts of a MTB, Virtual MTBs, and the generation of Real World Evidence, will be discussed.